Free Trial
NASDAQ:HYPD

Hyperion DeFi Q3 2025 Earnings Report

Hyperion DeFi logo
$3.24 +0.32 (+10.96%)
Closing price 04:00 PM Eastern
Extended Trading
$3.24 0.00 (0.00%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Hyperion DeFi EPS Results

Actual EPS
$0.05
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Hyperion DeFi Revenue Results

Actual Revenue
$0.36 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Hyperion DeFi Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Hyperion DeFi Earnings Headlines

Hyperion DeFi Reiterates Guidance on Sunset of USDH and Felix Markets
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst environment in 50 years - with portfolios potentially staying in the red for 10 years or longer. From rate spikes in 2022 to $12 trillion wiped out in 30 days during the Iran War, Wall Street suggests the volatility isn't slowing down. TradeSmith CEO Keith Kaplan is showing investors what steps to take now to prepare their wealth before this worsens.tc pixel
Hyperion DeFi Inc HYPD
See More Hyperion DeFi Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hyperion DeFi? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hyperion DeFi and other key companies, straight to your email.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

View Hyperion DeFi Profile